MXPA04003520A - Formulacion farmaceutica que comprende (r)-bicalutamida. - Google Patents
Formulacion farmaceutica que comprende (r)-bicalutamida.Info
- Publication number
- MXPA04003520A MXPA04003520A MXPA04003520A MXPA04003520A MXPA04003520A MX PA04003520 A MXPA04003520 A MX PA04003520A MX PA04003520 A MXPA04003520 A MX PA04003520A MX PA04003520 A MXPA04003520 A MX PA04003520A MX PA04003520 A MXPA04003520 A MX PA04003520A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- relates
- pharmaceutical formulation
- pka
- enantiomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se refiere a una formulacion farmaceutica que comprende el farmaco 4??-ciano-a??, a??, a??-trifluor-3 -(4-fluorofenilsulfonil) -2-hidroxi-2 -metilpripion-m -toluidida en una dispersion solida con un polimero enterico que tiene un pKa, de 3 a 6, en donde > 50% del farmaco se proporciona en la forma del R-enantiomero. La invencion tambien se refiere a una dosis farmaceutica diaria del farmaco proporcionado mediante tal formulacion. Ademas, la invencion se refiere al uso de un polimero enterico que tiene un pKa, de 3 a 6, en dispersion solida con el farmaco, en donde > 50% del farmaco se proporciona en la forma del R-enantiomero, para incrementar la bio-disponibilidad del farmaco, para reducir la variacion en concentraciones de plasma inter-paciente del farmaco; para mejorar la estabilidad al almacenamiento del farmaco; o para el uso en el tratamiento y/o la reduccion del riesgo de cancer de prostata en un paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103424A SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Pharmaceutical formulation |
| PCT/GB2002/004621 WO2003032950A1 (en) | 2001-10-15 | 2002-10-11 | Pharmaceutical formulation comprising (r) -bicalutamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04003520A true MXPA04003520A (es) | 2004-07-23 |
Family
ID=20285650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04003520A MXPA04003520A (es) | 2001-10-15 | 2002-10-11 | Formulacion farmaceutica que comprende (r)-bicalutamida. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060058381A1 (es) |
| EP (1) | EP1439823A1 (es) |
| JP (1) | JP3639587B2 (es) |
| KR (1) | KR20050035163A (es) |
| CN (1) | CN1571658A (es) |
| AR (1) | AR036877A1 (es) |
| BR (1) | BR0213248A (es) |
| CA (1) | CA2462219A1 (es) |
| CO (1) | CO5580755A2 (es) |
| HU (1) | HUP0401369A3 (es) |
| IL (1) | IL161306A0 (es) |
| IS (1) | IS7219A (es) |
| MX (1) | MXPA04003520A (es) |
| NO (1) | NO20041485L (es) |
| PL (1) | PL368226A1 (es) |
| RU (1) | RU2004115023A (es) |
| SE (1) | SE0103424D0 (es) |
| WO (1) | WO2003032950A1 (es) |
| ZA (1) | ZA200402729B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030077042A (ko) * | 2001-02-27 | 2003-09-29 | 아스트라제네카 아베 | 비칼루타마이드를 포함하는 약학 제제 |
| SI1715893T1 (sl) | 2004-01-20 | 2009-12-31 | Novartis Pharma Ag | Direktna kompresijska formulacija in postopek |
| CN101128195A (zh) * | 2005-02-23 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 用于递送增加的稳态血浆水平的比卡鲁胺 |
| US20080045600A1 (en) * | 2006-08-17 | 2008-02-21 | Gawande Rahul S | Bicalutamide compositions |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
| CN101987086B (zh) * | 2009-08-03 | 2012-07-18 | 北京化工大学 | 一种超细比卡鲁胺口服片剂及其制备方法 |
| CN103813794A (zh) * | 2011-07-18 | 2014-05-21 | 拓凯制药公司 | 用于治疗前列腺癌的新型组合物及方法 |
| ES2892029T3 (es) | 2012-09-11 | 2022-02-01 | Medivation Prostate Therapeutics Llc | Formulaciones de enzalutamida |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ， インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
| MA41107B1 (fr) * | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals, Inc. | Compositions anti-cancéreuses |
| LT3226843T (lt) | 2014-12-05 | 2021-08-10 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629237A (en) * | 1968-09-12 | 1971-12-21 | Shinetsu Chemical Co | Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them |
| US4309405A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| US4946686A (en) * | 1987-09-24 | 1990-08-07 | Merck & Co., Inc. | Solubility modulated drug delivery system |
| EP0580860B2 (en) * | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
| JPH09508125A (ja) * | 1994-01-21 | 1997-08-19 | セプラコー，インコーポレイテッド | 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
| KR20030077042A (ko) * | 2001-02-27 | 2003-09-29 | 아스트라제네카 아베 | 비칼루타마이드를 포함하는 약학 제제 |
| WO2002080902A1 (en) * | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
-
2001
- 2001-10-15 SE SE0103424A patent/SE0103424D0/xx unknown
-
2002
- 2002-10-11 CA CA002462219A patent/CA2462219A1/en not_active Abandoned
- 2002-10-11 RU RU2004115023/15A patent/RU2004115023A/ru not_active Application Discontinuation
- 2002-10-11 PL PL02368226A patent/PL368226A1/xx not_active Application Discontinuation
- 2002-10-11 KR KR1020047005493A patent/KR20050035163A/ko not_active Withdrawn
- 2002-10-11 US US10/492,629 patent/US20060058381A1/en not_active Abandoned
- 2002-10-11 HU HU0401369A patent/HUP0401369A3/hu unknown
- 2002-10-11 BR BR0213248-6A patent/BR0213248A/pt not_active Application Discontinuation
- 2002-10-11 CN CNA028203747A patent/CN1571658A/zh active Pending
- 2002-10-11 WO PCT/GB2002/004621 patent/WO2003032950A1/en not_active Ceased
- 2002-10-11 EP EP02770069A patent/EP1439823A1/en not_active Withdrawn
- 2002-10-11 MX MXPA04003520A patent/MXPA04003520A/es unknown
- 2002-10-11 AR ARP020103826A patent/AR036877A1/es unknown
- 2002-10-11 JP JP2003535754A patent/JP3639587B2/ja not_active Expired - Fee Related
- 2002-10-11 IL IL16130602A patent/IL161306A0/xx unknown
-
2004
- 2004-04-07 ZA ZA200402729A patent/ZA200402729B/xx unknown
- 2004-04-13 NO NO20041485A patent/NO20041485L/no not_active Application Discontinuation
- 2004-04-14 IS IS7219A patent/IS7219A/is unknown
- 2004-05-12 CO CO04043957A patent/CO5580755A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060058381A1 (en) | 2006-03-16 |
| CN1571658A (zh) | 2005-01-26 |
| JP2004521963A (ja) | 2004-07-22 |
| EP1439823A1 (en) | 2004-07-28 |
| PL368226A1 (en) | 2005-03-21 |
| AR036877A1 (es) | 2004-10-13 |
| ZA200402729B (en) | 2005-01-13 |
| CA2462219A1 (en) | 2003-04-24 |
| KR20050035163A (ko) | 2005-04-15 |
| HUP0401369A2 (hu) | 2004-11-29 |
| NO20041485L (no) | 2004-04-13 |
| CO5580755A2 (es) | 2005-11-30 |
| IS7219A (is) | 2004-04-14 |
| WO2003032950A1 (en) | 2003-04-24 |
| SE0103424D0 (sv) | 2001-10-15 |
| BR0213248A (pt) | 2004-09-28 |
| HUP0401369A3 (en) | 2006-05-29 |
| IL161306A0 (en) | 2004-09-27 |
| RU2004115023A (ru) | 2005-04-10 |
| JP3639587B2 (ja) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002067893A3 (en) | Pharmaceutical formulation comprising bicalutamide | |
| IL157955A0 (en) | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp | |
| MXPA04003520A (es) | Formulacion farmaceutica que comprende (r)-bicalutamida. | |
| HU0102039D0 (en) | Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby | |
| GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
| IL174561A0 (en) | Drug coating providing high drug loading and methods for providing the same | |
| WO2001085212A3 (en) | Drug delivery systems for photodynamic therapy | |
| GEP20053454B (en) | Aryl Fused Azapolycyclic Compounds, Composition Containing the Same and Use Thereof | |
| ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| MXPA03011538A (es) | Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal. | |
| IS6329A (is) | Lyf til að meðhöndla illkynja æxli | |
| DK1471892T3 (da) | Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer | |
| YU23202A (sh) | Lekovi za tretman malignih tumora | |
| SE0103839D0 (sv) | Pharmaceutical formulation & product | |
| BR0017120A (pt) | Composição farmacêutica | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| MXPA03010672A (es) | Composicion para el tratamiento regenerativo de enfermedades del cartilago. | |
| MXPA02008870A (es) | Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos. | |
| NO20026032D0 (no) | Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer | |
| SE0102887D0 (sv) | New formulation | |
| BR0213463A (pt) | Composições farmacêuticas contendo macrólidos | |
| SE0102888D0 (sv) | New formulation | |
| MXPA03010920A (es) | Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia. | |
| SE0102886D0 (sv) | New formulation |